Richest 1% create 20% of global warming, study finds
[Source]
A study published in Nature Climate Change finds that the wealthiest 1% of the global population are responsible for roughly 20% of global warming since 1990. The study examines emissions by income level rather than by country, revealing that wealthy individuals, regardless of nationality, are disproportionately responsible for rising global temperatures and extreme weather events.
Carbon inequality: The study, led by Sarah Schöngart and colleagues, found that the top 1% — those earning over about $160,000 annually — emit more than 20 times the carbon of the global average. The poorest half of the world's population, by contrast, contributed just 16% of warming since 1990.
Most emissions from the top earners are tied to high-consumption lifestyles, including air travel, luxury goods and fossil fuel investments. The gap between high and low emitters has widened over the past three decades.
Global damage, local costs: The study links emissions from wealthy individuals in high-emitting countries to rising heat and drought risks in vulnerable regions such as the Amazon, Southeast Asia and central Africa. In the Amazon, for example, emissions from the top 1% of Chinese earners have driven an 80% increase in extreme heat events. U.S. top 10% emitters are linked to more than 20 times the average global contribution to once-in-a-century heat waves.
Trending on NextShark:
National disparities: The study also highlights sharp inequalities within countries. In the U.S., the top 10% emit about three times more than the average citizen and 17 times more than the global average. In China and India, the top 10% also emit significantly above their fair share despite lower national averages.
Call for equitable climate policy: Researchers warn that climate action will fall short unless it addresses emissions from the top income groups. They call for policies such as progressive carbon pricing, restrictions on luxury emissions and increased climate finance for affected regions. The study concludes that without curbing emissions from the wealthiest, efforts to limit global warming to 1.5 degrees Celsius above pre-industrial levels are likely to fail.
Trending on NextShark:
This story is part of The Rebel Yellow Newsletter — a bold weekly newsletter from the creators of NextShark, reclaiming our stories and celebrating Asian American voices.
Subscribe free to join the movement. If you love what we're building, consider becoming a paid member — your support helps us grow our team, investigate impactful stories, and uplift our community.
Subscribe here now!
Trending on NextShark:
Download the NextShark App:
Want to keep up to date on Asian American News? Download the NextShark App today!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
2 hours ago
- Boston Globe
From no hope to a potential cure for a deadly blood cancer
A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients -- a result never before seen in this disease. Advertisement These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words 'potential cure.' Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'In my 30 years in oncology, we haven't talked about curing myeloma,' said Dr. Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. 'This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.' The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which has an exclusive licensing agreement with Legend Biotech. The 36,000 Americans who develop multiple myeloma each year face an illness that eats away at bones, so it looks as if holes have been punched out in them, said Dr. Carl June, of the University of Pennsylvania. Bones collapse. June has seen patients who lost 6 inches in height. Advertisement 'It's a horrible, horrible death,' June said. 'Right now advanced myeloma is a death sentence.' (June has immunotherapy patents that are owned by his university.) There have been treatment advances that increased median survival from two years to 10 over the past two decades. But no cures. Dr. Peter Voorhees of the Atrium Health Levine Cancer Institute in North Carolina and the Wake Forest University School of Medicine, who is lead researcher for the newly published study, said patients usually go through treatment after treatment until, ultimately, the cancer prevails, developing resistance to every class of drug. They end up with nothing left to try. The Legend immunotherapy is a type known as CAR-T. It is delivered as an infusion of the patient's own white blood cells that have been removed and engineered to attack the cancer. The treatment has revolutionized prospects for patients with other types of blood cancer, like leukemia. Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it can have severe side effects including a high fever, trouble breathing and infections. Patients can be hospitalized for weeks after receiving it. But Legend managed to develop one that works in multiple myeloma, defying skeptics. The Chinese company gained attention for its CAR-T eight years ago when it made extravagant claims, which were met by snickers from American researchers. Advertisement Johnson & Johnson, though, was looking for a CAR-T to call its own. So, said Mark Wildgust, an executive in the oncology section of the American drug giant, the company sent scientists and physicians to China to see if the claims were true. 'We went site by site to look at the results,' he said. The company was convinced. It initiated a collaboration with Legend and began testing the treatment in patients whose myeloma had overcome at least one standard treatment. Compared with patients who had standard treatment, those who had the immunotherapy lived longer without their disease progressing. The immunotherapy received regulatory approval in that limited setting and is sold under the brand name Carvykti. The study did not determine whether this difficult treatment saved lives. The new study took on a different challenge -- helping patients at the end of the line after years of treatments. Their immune systems were worn down. They were, as oncologists said, 'heavily pretreated.' So even though CAR-T is designed to spur their immune systems to fight their cancer, it was not clear their immune systems were up to it. Oncologists say that even though most patients did not clear their cancer, having a third who did was remarkable. To see what the expected life span would be for these patients without the immunotherapy, Johnson & Johnson looked at data from patients in a registry who were like the ones in its study -- they had failed every treatment. They lived about a year. For Anne Stovell of New York, one of the study patients whose cancer disappeared, the result is almost too good to be true. She says she went through nine drugs to control her cancer after it was diagnosed in 2010, some of which had horrendous side effects. Each eventually failed. Advertisement Taking the Legend CAR-T was difficult -- she said she had spent nearly three weeks in the hospital. But since that treatment six years ago, she has no sign of cancer. She said it was still difficult for her to believe her myeloma is gone. A new ache -- or an old one -- can bring on the fear. 'There's that little seed of doubt,' she said. But in test after test, the cancer has not reappeared. 'It's a relief for me every year to get a bone marrow biopsy,' she said. Myeloma experts applauded the results. Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are 'hideously expensive,' June said, costing more than $100,000 a year. The total cost over the years can be millions of dollars, June said, usually paid by insurers, 'and it doesn't even cure you.' CAR-T is expensive too. Carvykti's list price is $555,310. But it is a one-time treatment. And, more important, the hope is that perhaps by giving it earlier in the course of the disease, it could cure patients early on. Johnson & Johnson is now testing that idea. Dr. Kenneth Anderson, a myeloma expert at Dana-Farber Cancer Institute who was not involved with the study, said that if the treatment is used as a first-line treatment, 'cure is now our realistic expectation.' That, at least, is the hope, Sharpless said. And for those like the patients in the new study who are living at least five years -- so far -- without disease, the outcome 'really is eye-popping,' Sharpless said. Advertisement 'That's getting to a point where you wonder if it will ever come back,' he added. This article originally appeared in
Boston Globe
4 hours ago
- Boston Globe
US says it broke up effort to bring toxic fungus to Michigan lab from China
Yunqing Jian, 33, and Zunyong Liu, 34, were charged with conspiracy, smuggling, making false statements and visa fraud. 'The alleged actions of these Chinese nationals, including a loyal member of the Chinese Communist Party, are of the gravest national security concerns,' U.S. Attorney Jerome Gorgon Jr. said. Advertisement Jian appeared in court and was returned to jail to await a bond hearing Thursday. An attorney who was assigned only for her initial appearance declined to comment. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up In July 2024, Liu was turned away at the Detroit airport and sent back to China after changing his story during an interrogation about red plant material discovered in his backpack, the FBI said. He initially claimed ignorance about the samples but later said he was planning to use the material for research at a University of Michigan lab where Jian worked and where Liu previously worked, the FBI said. The FBI said authorities found a scientific article on Liu's phone that was titled, 'Plant-Pathogen Warfare under Changing Climate Conditions.' A week before arriving in the U.S., according to investigators, Liu exchanged messages with Jian, who said, 'It's a pity that I still have to work for you.' Advertisement The FBI said Liu replied: 'Once this is done, everything else will be easy.' Months later, in February, FBI agents visited Jian at the campus lab. She said, '100% no,' when asked if she had been assisting Liu with the pathogen at the lab. The FBI said it found a signed statement on her phone expressing her support for the Communist Party of China. Messages between the two in 2024 suggest that Jian was already tending to Fusarium graminearum at the campus lab before Liu was caught at the Detroit airport, the FBI said. The university does not have federal permits to handle it. The U.S. does not have an extradition treaty with China, which makes Liu's arrest unlikely unless he returns.
Yahoo
6 hours ago
- Yahoo
Chinese nationals accused of smuggling 'dangerous biological pathogen' into US
Two Chinese nationals have been accused of smuggling a fungus into the US that officials describe as a "dangerous biological pathogen". Yunqing Jian, 33, and Zunyong Liu, 34, have been charged with conspiracy, smuggling goods, false statements, and visa fraud, the US Attorney's Office for the Eastern District of Michigan announced on Tuesday. The complaint alleges Mr Liu tried to smuggle the fungus through Detroit airport so he could study it at a University of Michigan laboratory where his girlfriend, Ms Jian, worked. The fungus called Fusarium graminearum can cause a disease in wheat, barley, maize and rice that can wipe out crops and lead to vomiting and liver damage if it gets into food. The fungus is described in scientific literature as a "potential agroterrorism weapon", according to the US Attorney's Office, adding it is responsible for "billions of dollars in economic losses worldwide each year." Officials further allege Ms Jian received funding from the Chinese government for her research on the pathogen in China. They also claim she is a member of the Chinese Communist Party. United States Attorney Jerome F Gorgon Jr described the allegations as of the "gravest national security concerns". "These two aliens have been charged with smuggling a fungus that has been described as a 'potential agroterrorism weapon' into in the [sic] heartland of America, where they apparently intended to use a University of Michigan laboratory to further their scheme." The investigation was a joint effort between the FBI and US Customs and Border Protection. Ms Jian is due to appear in court in Detroit, Michigan on Tuesday. The BBC has reached out to the University of Michigan and the Chinese embassy in Washington DC for comment. The charges come amid strained relations between the US and China, and just days after the Trump administration vowed to "aggressively" revoke the visas of Chinese nationals studying in the US. Beijing also said Washington "severely violated" a trade truce reached in Geneva last month, when both countries lowered tariffs on goods imported from each other. Earlier this week, a Chinese student at the University of Michigan was charged for illegally voting in the October 2024 election. Harvard Chinese grad speech draws praise and ire Hegseth warns China poses 'imminent' threat to Taiwan and urges Asia to boost defence US and China struggle for dominance as officials meet for Shangri-La Dialogue
